Immunic, Inc. (IMUX) Financial Ratios
15 years of historical data (2011–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↑
N/A
—
5yr avg: 2.48
30Y Low0.4·High6.1
ROE
↓
-1653.1%
↑-248% vs avg
5yr avg: -474.8%
30Y Low-424%·High-41%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
IMUX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Immunic, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $129M | $83M | $100M | $66M | $45M | $226M | $239M | $75M | $8M | $237M | $137M |
| Enterprise Value | $114M | $68M | $66M | $21M | $-60635386 | $140M | $113M | $46M | $32M | $180M | $77M |
| P/E Ratio → | -2.09 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | 21620.91 |
| P/B Ratio | — | — | 5.44 | 2.30 | 0.39 | 1.78 | 1.51 | 1.28 | 0.63 | 4.74 | 2.34 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
IMUX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | — | — | — | — | — | — | — | — | 12121.15 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
IMUX Profitability
Margins and return-on-capital ratios measuring operating efficiency
A negative ROE of -1653.1% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | -28529.7% |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | -653447.6% |
| Net Profit Margin | — | — | — | — | — | — | — | — | — | — | -648744.6% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -1653.1% | -1653.1% | -424.4% | -131.3% | -100.0% | -65.0% | -40.5% | -98.4% | -132.8% | -96.0% | -58.2% |
| ROA | -299.4% | -299.4% | -211.2% | -102.8% | -90.2% | -60.6% | -37.7% | -86.1% | -110.1% | -83.7% | -53.5% |
| ROIC | — | — | — | — | -360.3% | -186.9% | -118.8% | -84.4% | -214.1% | — | — |
| ROCE | -1702.4% | -1702.4% | -406.3% | -137.6% | -98.6% | -63.8% | -44.9% | -103.8% | -134.3% | -96.9% | -58.5% |
IMUX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $15M exceeds total debt of $684000, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.05 | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 2.99 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -1.88 | -1.57 | -0.93 | -0.68 | -0.80 | -0.49 | 1.92 | -1.14 | -1.03 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -83.11 | — | — | -346.09 | — | — | — |
Net cash position: cash ($15M) exceeds total debt ($684000)
IMUX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.75x is below 1.0, meaning current liabilities exceed current assets. The current ratio has declined from 2.12x to 0.75x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.75 | 0.75 | 1.77 | 2.12 | 9.62 | 9.21 | 15.93 | 4.56 | 5.67 | 5.65 | 11.22 |
| Quick Ratio | 0.75 | 0.75 | 1.77 | 2.12 | 9.20 | 9.21 | 15.93 | 4.62 | 5.75 | 5.65 | 11.22 |
| Cash Ratio | 0.51 | 0.51 | 1.61 | 1.89 | 8.90 | 7.62 | 15.18 | 4.15 | 5.31 | 5.53 | 10.95 |
| Asset Turnover | — | — | — | — | — | — | — | — | — | — | 0.00 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | — | — | — | — | — | — |
IMUX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Immunic, Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $16M | $10M | $4M | $3M | $2M | $2M | $772227 | $105923 | $99648 | $78469 |
Peer Comparison
Compare IMUX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 IMUXYou | $129M | -2.1 | — | — | — | — | -1653.1% | — | — |
 ARQT | $3B | -189.2 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 VNDA | $361M | -1.6 | — | — | 94.0% | -70.0% | -50.9% | -32.2% | — |
 PRAX | $7B | -18.4 | — | — | — | — | -45.8% | -65.0% | — |
 ACAD | $4B | 9.3 | 25.5 | 34.8 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 IDYA | $3B | -22.5 | — | — | 97.9% | -72.8% | -10.9% | -12.4% | — |
 TGTX | $7B | 17.3 | 61.0 | — | 83.7% | 20.0% | 102.8% | 16.4% | 2.1 |
 GILD | $156B | 18.6 | 12.0 | 16.5 | 78.8% | 39.7% | 40.7% | 23.2% | 1.7 |
 BIIB | $30B | 22.6 | 11.9 | 14.4 | 70.5% | 19.1% | 7.4% | 6.5% | 2.5 |
 INCY | $22B | 16.8 | 12.9 | 15.9 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 ABBV | $398B | 94.8 | 16.3 | 22.3 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
| Healthcare Median | — | 23.1 | 14.4 | 19.0 | 64.0% | -4.2% | -32.6% | -11.2% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 15 years · Updated daily
What if you invested $1,000 in IMUX 10 years ago?
Total return calculator · dividends reinvested
Calculate ReturnsHow much would $100/month in IMUX be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs IMUX Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationIMUX vs ARQT — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Arcutis Biotherapeutics, Inc..
Compare NowIMUX — Frequently Asked Questions
Quick answers to the most common questions about buying IMUX stock.
What is Immunic, Inc.'s P/E ratio?
Immunic, Inc.'s current P/E ratio is -2.1x. This places it at the 50th percentile of its historical range.
What is Immunic, Inc.'s ROE?
Immunic, Inc.'s return on equity (ROE) is -1653.1%. The historical average is -122.2%.
Is IMUX stock overvalued?
Based on historical data, Immunic, Inc. is trading at a P/E of -2.1x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.